ArticleScientific reports2026
Thyroid cancer detection and classification using spectral imaging and artificial intelligence.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genomics and Multi-Omics to Guide Clinical Management in Thyroid Cancer.International journal of molecular sciences · 2026Review
- Portable Multispectral Optoelectronic System for Thyroid Cancer Detection.Sensors (Basel, Switzerland) · 2026Article
- Hyperspectral imaging system for multiplexed cancer marker detection: design and clinical evaluation.Journal of biomedical optics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Thyroid cancer is the most prevalent endocrine cancer, with a steadily rising incidence. Its diagnosis involves microscopic examination of tissue specimens, a process that can lead to misclassification with critical prognostic consequences. Numerous artificial intelligence techniques have been proposed for thyroid cancer detection, however, none have proven clinically relevant. We present an accurate diagnostic approach based on a newly developed spectral imaging system that rapidly measures the visible spectrum at each point on routinely prepared hematoxylin and eosin-stained tissue sections. These spectral images are analyzed with machine learning algorithms, classifying each nucleus while preserving interpretability for experts. The integration of spectral imaging and artificial intelligence enables precise, robust identification of normal and tumor cells, offering a straightforward, powerful approach for thyroid cancer assessment. By utilizing routinely stained tissue specimens and targeting specific pathological features, our method provides a tool to support pathologists, facilitating accurate and timely evaluations of thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.